Development of a GFRAL antagonistic antibody for the amelioration of cancer cachexia
- Title
- Development of a GFRAL antagonistic antibody for the amelioration of cancer cachexia
- Alternative Title
- 암 악액질 증상 개선을 위한 GFRAL 길항 항체 개발
- Author(s)
- Beom Yong Lee
- DGIST Authors
- Beom Yong Lee ; Kyungmoo Yea ; Byung-Hoon Lee
- Advisor
- 예경무
- Co-Advisor(s)
- Byung-Hoon Lee
- Issued Date
- 2022
- Awarded Date
- 2022/02
- Type
- Thesis
- Description
- Cancer cachexia, cisplatin, GDF15, GFRAL, antibody
- Table Of Contents
-
I. Introduction 1
1.1 Chemotherapy-induced cachexia 1
1.2 Growth differentiation factor 15 (GDF15) 1
1.3 GDF15/GFRAL/RET axis 2
1.4 Aims and objectives 2
II. Materials & Methods 4
2.1 Biopanning 4
2.2 Enzyme-linked immunosorbent assay (ELISA) 4
2.3 Antibody purification 5
2.4 Surface plasmon resonance (SPR) spectrometry 5
2.5 Cells and cell culture 5
2.6 Luciferase reporter assay 6
2.7 Flow cytometry analysis 6
2.8 Immunofluorescence staining 7
2.9 Western blot analysis 7
2.10 Animals and in vivo experiments 8
2.11 Statistical analysis 8
III. Results 9
3.1 GFRAL antagonist antibody was selected by biopanning using human combinatorial antibody phage libraries 9
3.2 Antibody A11 binds to GFRAL and potently suppresses the GDF15/GFRAL/RET axis 12
3.3 Antibody A11 attenuates cisplatin-induced cachexia through inhibition of the GDF15/GFRAL/RET axis in vivo 15
3.4 Antibody A11 alleviates cisplatin-induced cachexia in melanoma-bearing mice 19
IV. Discussion 24
V. References 26
VI. Summary 28
- URI
-
http://dgist.dcollection.net/common/orgView/200000593969
http://hdl.handle.net/20.500.11750/16271
- Degree
- Master
- Department
- New Biology
- Publisher
- DGIST
- Related Researcher
-
-
Yea, Kyungmoo
- Research Interests Antibody; Engineering; Phage Display; Therapeutics; Immune; Exosome; Translational; Cytokine
-
- Files in This Item:
-
There are no files associated with this item.
- Appears in Collections:
- Department of New Biology Theses Master
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.